This website is intended for healthcare professionals only.
FIRST LINE TREATMENT OF CHILDREN WITH ALL AND MANAGEMENT OF ASPARARGINASE -ASSOCIATED HYPERSENSITIVITY - INSIGHTS FROM THE US
Prof Michael J. Burke Division of Pediatric Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
This webinar presented data on first-line treatment of children with ALL and management of asparaginase-associated hypersensitivity. It discussed how hypersensitivity reactions may be confused with infusion reactions. Expert recommendations were given for therapeutic drug monitoring and management of hypersensitivity reactions, along with a clinical pathway for classification and management of adverse reactions to asparaginase.
Key points covered
This webinar presented first-line treatment of children with ALL and management of asparaginase-associated hypersensitivity
Hypersensitivity vs infusion reactions
Measuring asparaginase activity
Hypersensitivty incidence in COG trials
Management of Hypersensitivty
Webinar Replay
Featured Speakers
Professor Michael J. Burke
Dr. Michael Burke is a Professor at the Medical College of Wisconsin, Department of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplantation. He is the Director of the Leukemia & Lymphoma Program at Children’s Hospital of Wisconsin. He has developed early phase and upfront clinical trials in acute leukemia that have opened locally as well as nationally through consortiums such as the Children’s Oncology Group (COG) and the Therapeutic Advances in Childhood Leukemia & Lymphoma.
